Mediators of Inflammation

Research Article

Antagonizing Arachidonic Acid-Derived Eicosanoids Reduces Inflammatory Th17 and Th1 Cell-Mediated Inflammation and Colitis Severity

Table 1

Colonic mucosal eicosanoid and cannabinoid profiles in Wt and Fat-1 TNBS-treated mice¹.


Eicosanoid (ng/mg protein)	Wt	Fat-1

PGE₁	0.68 ± 0.16	1.00 ± 0.35
PGE₂	13.79 ± 3.46	7.50 ± 1.79*
PGE₃	0.00 ± 0.00	0.24 ± 0.03*
PGD₂	44.37 ± 2.09	23.18 ± 5.69*
	4.16 ± 0.64	2.40 ± 0.59*
6-keto-	3.65 ± 0.73	2.05 ± 0.35
TXB₂	1.02 ± 0.16	0.85 ± 0.28
13-PGE₁	0.02 ± 0.01	0.00 ± 0.00
13-PGE₂	11.33 ± 2.36	7.68 ± 1.27
13-HODE	12.29 ± 2.68	8.33 ± 0.87
5-HETE	1.01 ± 0.18	0.93 ± 0.35
12-HETE	7.74 ± 2.22	8.40 ± 3.69
15-HETE	0.97 ± 0.13	0.50 ± 0.15*
AEA	44.10 ± 3.89	19.97 ± 6.35*
2-AG	0.50 ± 0.05	0.24 ± 0.03*

Mean values ± SEM of TNBS-treated Fat-1 mice ( = 4-5/genotype) and values marked with an asterisk differ from Wt (). PG, prostaglandin; TX, thromboxane; 13-PGE₁, 13,14-dihydro 15-keto-PGE₁; 13-PGE₂, 13,14-dihydro 15-keto-PGE₂; HODE, hydroxyl-octadecadienoic acid; HETE, hydroxyl-eicosatetraenoic acid; AEA, arachidonoyl ethanolamine; and AG, arachidonoyl glycerol.